HIM
RNAC icon

Hillsdale Investment Management’s Cartesian Therapeutics RNAC Stock Holding History

Hillsdale Investment Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-280
Closed -$144K – 527
2016
Q4 		$144K Buy
+280
New +$164K 0.03% 297

Other funds holding RNAC

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hillsdale Investment Management's RNAC Position: Q1 2017 in Review

Hillsdale Investment Management sold out of Cartesian Therapeutics (RNAC) in Q1 2017, closing a stake of 280 shares — an estimated $144K sold.

Hillsdale Investment Management first reported a position in RNAC in Q4 2016 and held it in 1 quarter. The position peaked at $144K in Q4 2016. 46 funds tracked by Wall St. Rank hold RNAC as of Q1 2017.

  • Hillsdale Investment Management reported no remaining Cartesian Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Hillsdale Investment Management sold 280 Cartesian Therapeutics shares in Q1 2017, an estimated $144K.
  • Hillsdale Investment Management first reported a position in Cartesian Therapeutics in Q4 2016 and held it in 1 quarter.
  • Hillsdale Investment Management's Cartesian Therapeutics position peaked at $144K in Q4 2016.
  • 46 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2017.

Based on Hillsdale Investment Management's 13F filing for Q1 2017, filed 9 May 2017.